NewAmsterdam Pharma Company N.V.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $19.74
- 52-Week Range
- $17.90 – $42.21
- Market Cap
- $2.34B
- P/E (TTM)
- —
- EPS (TTM)
- -1.69
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 3.71
- PEG Ratio
- —
- Return on Equity
- -30.16%
- Return on Assets
- -19.79%
- Gross Margin
- 100.00%
- Operating Margin
- -900.07%
- Profit Margin
- 0.00%
- Current Ratio
- 11.76
- Debt/Equity
- 0.00
- Total Debt
- $76.00K
- Free Cash Flow
- $-98.63M
- Revenue Growth
- 5406.90%
- Earnings Growth
- —
- Enterprise Value
- $1.74B
Market Snapshot
About
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company developing oral therapies for cardiovascular disease. The company focuses on lipid-lowering treatments targeting patients with high cholesterol who remain at risk despite current therapies.